Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: xomadog2 who wrote (9436)	3/30/1999 7:29:00 AM
From: Robert K.	Respond to of 17367

Xomadog>good post, lots of good points. A comment on your comment>>> "To Robert K. Thank you and keep digging but I think you have not even found the tip of the iceberg. GNE wont let you..Good luck.!" My comment>true, but I have more than enough leads to know how big the iceberg(s) might "potentially" be. And I am following them up. Good luck. Standard K disclaimer.

To: xomadog2 who wrote (9436)	3/30/1999 9:47:00 AM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

NOTHING WOULD PLEASE ME MORE THAN FOR XOMA TO SUE ME! BRING IT ON! In my opinion it looks like you are now hyping the stock.

To: xomadog2 who wrote (9436)	3/30/1999 3:43:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

You may think a trial has not started and that GNE and or XOMA would say something when it had. I do not know if you read the announcement with care or not. Criteria for selection were outlined, they differed from prior criteria, people with previous head injuries had been excluded. A final date after which no further accruals will be made was given as of Jan. 2000. Questioners are being sent out to all those that have an interest. None of these things would be done if the FDA had not approved the trial design. The question for many of us is not whether a trial has started but the final dotting of the eyes to be sure XOMA is involved, and that this is indeed the P III continuance. You might feel that XOMA does not need to say anything until it gets ready to. I differ with you. A major question for shareholders was would GNE select XOMA to manage the P III trial. Also having a company with 3 P III trials going is also newsworthy. The management of XOMA know it has had a core of loyal shareholders but they need to know that not every move they make will be applauded. They have, IMO, the best IR dept. of any company I have ever encountered. My concern is that sometimes upper management thinks they know better and does stupid, yes stupid, things in this area.